Middle East and Africa Intravenous Immunoglobulin Market

The intravenous immunoglobulin market in the MEA is expected to grow from US$ 497.97 million in 2022 to US$ 711.99 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.

Rising Prevalence of Immunodeficiency Diseases

Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.

Market Overview

The Middle East & Africa intravenous immunoglobulin market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia was this region's largest intravenous immunoglobulin market in 2021. The Middle East & Africa intravenous immunoglobulin market is anticipated to grow at a CAGR of 6.1% during the forecast period; this growth can be attributed to the increasing government support for healthcare and the rising awareness regarding IgRT. The increasing prevalence of GBS and infectious diseases drives the intravenous immunoglobulin market in Saudi Arabia. According to the article, "Application of intravenous immunoglobulin (IVIg) to modulate inflammation in critical COVID-19," published in the National Library of Medicine (NLM) in 2021, administration of IVIg within a specific dosage was extremely beneficial toward reducing mortality and perhaps even the length of hospitalization of patients exhibiting severe COVID-19 symptoms.

MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

Middle East and Africa Intravenous Immunoglobulin Strategic Insights

Strategic insights for the Middle East and Africa Intravenous Immunoglobulin provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Intravenous Immunoglobulin Report Scope

Middle East and Africa Intravenous Immunoglobulin Regional Insights

The geographic scope of the Middle East and Africa Intravenous Immunoglobulin refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

MEA Intravenous Immunoglobulin Market Segmentation

The MEA intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

Based on application, the MEA intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.

Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.

Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.

Based on country, the market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. Saudi Arabia dominated the market in 2022.

ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.